Ichiro Abe 2020. Efficacy and Safety of Low-Dose Ipragliflozin, a Selective Sodium Glucose Transporter 2 Inhibitor, in Patients with Type 2 Diabetes Mellitus. International Journal of Allied Medical Sciences and Clinical Research. 4, 3 (Aug. 2020), 376–382. DOI:https://doi.org/10.61096/ijamscr.v4.iss3.2016.376-382.